Sonnet biotherapeutics announces issuance of u.s. patent for platform technology

U.s. patent and trademark office issued us patent no. 11,028,166 for the company's fully human albumin binding domain fusion proteins princeton, nj / accesswire / june 8, 2021 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the united states patent and trademark office (uspto) has issued u.s. patent no.
SONN Ratings Summary
SONN Quant Ranking